BIO VIEW (Israel) Top Management

BIO VIEW employes about 12 people. The company is managed by 13 executives with total tenure of roughly 154 years, averaging almost 11.0 years of service per executive having 0.92 employees per reported executive. Analysis of BIO VIEW management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with BIO VIEW future performance.
Check out Trending Equities.
  
  Yuval Harari  CEO
Co-CEO, Director
  David Kutas  CEO
CEO of BioView Inc - USA and President of BioView Inc - USA
  Alan Schwebel  CEO
CEO and Pres

BIO VIEW Management Team Effectiveness

BIO VIEW has return on total asset (ROA) of (3.69) % which means that it has lost $3.69 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (6.08) %, meaning that it generated substantial loss on money invested by shareholders. BIO VIEW management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.

BIO VIEW Workforce Comparison

BIO VIEW is number one stock in number of employees category among related companies. The total workforce of Medical Devices industry is currently estimated at about 24.0. BIO VIEW totals roughly 12.0 in number of employees claiming about 50% of all equities under Medical Devices industry.

BIO VIEW Profit Margins

The company has Profit Margin (PM) of (5.03) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (5.93) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.06.

BIO VIEW Notable Stakeholders

A BIO VIEW stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as BIO VIEW often face trade-offs trying to please all of them. BIO VIEW's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting BIO VIEW's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Yuval Harari - Co-CEO, DirectorProfile
David Kutas - CEO of BioView Inc - USA and President of BioView Inc - USAProfile
Alan Schwebel - CEO and PresProfile
Emmanuel Gill - Chairman of the BoardProfile
Elad Kfir - Vice President of MarketingProfile
Inbal Hillel - Vice President - OperationsProfile
Marina Wolfson - CFOProfile
Eliane Markowitz - External DirectorProfile
Yacha Sutton - DirectorProfile
Jackie RosenblumGoren - External DirectorProfile
Lior Shav - DirectorProfile
Eliyahu AyalonLanciano - External DirectorProfile
Warren Esanu - DirectorProfile

BIO VIEW Workforce Analysis

Traditionally, organizations such as BIO VIEW use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare BIO VIEW within its industry.

BIO VIEW Manpower Efficiency

Return on BIO VIEW Manpower

Revenue Per Employee2.3 M
Revenue Per Executive2.1 M
Net Loss Per Employee114.2 K
Net Loss Per Executive105.4 K
Working Capital Per Employee1.5 M
Working Capital Per Executive1.4 M
Check out Trending Equities. You can also try Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Tools for BIO VIEW Stock

When running BIO VIEW price analysis, check to measure BIO VIEW's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BIO VIEW is operating at the current time. Most of BIO VIEW's value examination focuses on studying past and present price action to predict the probability of BIO VIEW's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move BIO VIEW's price. Additionally, you may evaluate how the addition of BIO VIEW to your portfolios can decrease your overall portfolio volatility.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go